Talk:Ancillary testing in prostate cancer: Difference between revisions
Jump to navigation
Jump to search
Created page with "MSI testing - in BRCA1/2: {{cite journal |vauthors=Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R..." |
No edit summary |
||
| Line 1: | Line 1: | ||
MSI testing - in BRCA1/2: {{cite journal | | MSI testing - in BRCA1/2: {{cite journal |authors=Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O |title=Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA |journal=J Immunother Cancer |volume=8 |issue=2 |pages= |date=August 2020 |pmid= |pmc=7422632 |doi=10.1136/jitc-2020-001065 |url=}} | ||
Latest revision as of 15:20, 1 November 2022
MSI testing - in BRCA1/2: Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O (August 2020). "Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA". J Immunother Cancer 8 (2). doi:10.1136/jitc-2020-001065. PMC 7422632. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422632/.